Certain dopamine blockers may be tied to faster Huntington’s progression

Study authors urge future trials to account for ADM use in study design

Written by Marisa Horak, MS |

A patient holds a prescription medication bottle while conferring with a clinician holding a clipboard.

The use of certain antidopaminergic medications may be linked to a faster progression of Huntington's disease, according to a new analysis of clinical trial data. (Photo from iStock)

The use of certain antidopaminergic medications (ADMs), or those that block the activity of a brain signaling molecule called dopamine, may be linked to a faster progression of Huntington’s disease, according to a new analysis of clinical trial data.

“Our study is not intended to inform changes to the current standard-of-care or guide clinical decision-making in HD [Huntington’s disease],” researchers wrote.

“The important learning from this data, is to carefully consider the potential impact ADMs may have when designing or interpreting a clinical study,” added Karen Anderson, MD, the study’s first author at Georgetown University Medical Center, in a joint press release from Prilenia Therapeutics and Ferrer. “Taking ADMs may affect how someone scores on different [Huntington’s] measures, potentially influencing the outcome of the study, so we really need to think about ADMs not just as a concomitant medication that we record in a logbook, but as an integral part of the study design.”

Prilenia and Ferrer are jointly developing pridopidine, an experimental treatment for Huntington’s that is being tested against a placebo in a global Phase 3 clinical trial, PRECISE-HD (NCT07609108), whose design was informed by these findings. Up to 400 adults with early or early-intermediate stages of Huntington’s who are not taking ADMs are expected to be recruited.

The new findings were described in the study “Antidopaminergic Medications and Clinical Outcomes in Huntington Disease Evidence From the PROOF-HD Placebo-Controlled Trial,” which was published in Neurology. The work was funded by Prilenia, and several of the study’s authors are company employees.

Recommended Reading
A half-filled liquid medication bottle bears a label reading

Experimental therapy lowers mutant Huntington’s protein

Severity scores worsened faster in patients taking ADMs

While there is no approved Huntington’s treatment that can slow disease progression, available treatments can help ease symptoms of this genetic, neurodegenerative disease. Many of these treatments, including those approved for chorea (involuntary movements) and antipsychotics used for mental health problems, are antidopaminergic medications.

“Observational evidence suggests that ADM use may be associated with accelerated worsening of clinical outcome measures used in HD trials, but this relationship has not been examined in a controlled trial setting,” the researchers wrote.

With this in mind, a team of researchers investigated the relationship between ADM use and Huntington’s progression using data from the Phase 3 PROOF-HD clinical trial (NCT04556656), which tested pridopidine against a placebo in nearly 500 adults with early-stage Huntington’s.

Specifically, this analysis focused on the nearly 250 trial participants who were given the placebo, more than half of whom were on ADMs during the study.

Results showed that scores on the composite Unified Huntington’s Disease Rating Scale (cUHDRS), a validated measure of Huntington’s severity, worsened significantly faster in participants taking ADMs.

In this study, antidopaminergic medications appeared to have had an impact across various areas of the disease, with results showing a greater worsening of clinical measures in HD participants who were on ADMs.

A statistically significant difference between the ADM and non-ADM groups was detectable after about nine months, and the non-ADM group had significantly better scores over the course of follow-up out to about 1.5 years.

Scores on Total Functional Capacity (TFC), a cUHDRS subscore that assesses a patient’s daily life functioning, showed similar findings, with statistically significant differences favoring the non-ADM group over the ADM group over the course of follow-up.

Other measures, including assessments of cognitive function and motor symptoms, showed the same trends, with results consistently suggesting worse long-term disease progression in patients on ADMs.

“In this study, antidopaminergic medications appeared to have had an impact across various areas of the disease, with results showing a greater worsening of clinical measures in HD participants who were on ADMs,” Anderson said.

Recommended Reading
An illustration for a clinical trial features the words

First US patients dosed in trial of experimental Huntington’s treatment

Findings don’t prove ADMs directly cause faster disease progression

Still, the researchers stressed that these findings don’t prove that ADMs directly cause faster disease progression — other factors may also play a role. For example, it’s possible that patients who are experiencing faster progression may be more likely to be given ADMs rather than the other way around.

“ADMs remain an important component of symptom management and should not be interpreted as a reason to exclude patients receiving ADMs from clinical trials,” the team wrote. “Future HD trials should prospectively stratify by ADM exposure status and report outcomes separately by subgroup, particularly where a treatment interaction is plausible.”

Of note, in the PROOF-HD study, pridopidine failed to outperform the placebo at improving TFC scores, but subgroup analyses suggested potential benefits specifically among patients not on ADMs.

Michael Hayden, PhD, Prilenia’s CEO and the study’s senior author, said the analysis of PROOF-HD’s placebo group “provided key insights for the rationale and design of the PRECISE-HD study that makes it different from other trials.”

PRECISE-HD “has been consciously designed to ensure that patients are not on ADMs at baseline [study’s start], while maintaining, as part of the study protocol, the ability to use selected ADMs at doses described in product labeling when deemed medically necessary,” Hayden added. “This ensures that we decrease as much [variability] at baseline as possible, so that we increase our chances of observing a study result that is useful to the HD community within the bounds and duration of the study.”

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.